Analysis

Absci Corporation Reports 2021 Results, Announces NVIDIA Partnership

03/23/2022

News

Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?

Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

04/10/2024

Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?

Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

03/01/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Absci Corporation (ABSI) a buy, sell, or hold?

Absci Corporation (ABSI) can sell. Click on Rating Page for detail.

What is Absci Corporation's stock price?

The price of Absci Corporation (ABSI) is 4.58 and it was updated on 2024-04-27 07:00:40.

Is Absci Corporation (ABSI) overvalued or undervalued?

Currently Absci Corporation (ABSI) is in undervalued.

News

From:

To:

News
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year? Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year. Mon, Feb. 05, 2024
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%. Tue, Dec. 05, 2023
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday. Sun, Dec. 03, 2023
Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences in New York, NY. Thu, Oct. 26, 2023
Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. Mon, Aug. 28, 2023

Transcripts

Transcipts Data
Absci Corporation (ABSI) on Q3 2021 Results - Earnings Call Transcript SA Transcripts Sun, Nov. 14, 2021

SEC Filings

SEC Filings
Absci Corporation (ABSI) - DEFA14A SEC Filings 04/23/2024
Absci Corporation (ABSI) - DEF 14A SEC Filings 04/23/2024
Absci Corporation (ABSI) - ARS SEC Filings 04/23/2024
Absci Corporation (ABSI) - S-8 SEC Filings 03/21/2024
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 03/21/2024
Absci Corporation (ABSI) - 4 SEC Filings 03/21/2024
Absci Corporation (ABSI) - 10-K - Current report SEC Filings 03/21/2024
Absci Corporation (ABSI) - SC 13D/A SEC Filings 03/05/2024
Absci Corporation (ABSI) - 4 SEC Filings 03/05/2024
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 02/28/2024
Absci Corporation (ABSI) - 424B5 SEC Filings 02/28/2024
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 02/27/2024
Absci Corporation (ABSI) - 424B5 SEC Filings 02/27/2024
Absci Corporation (ABSI) - SC 13G/A SEC Filings 02/14/2024
Absci Corporation (ABSI) - 5 SEC Filings 02/14/2024
Absci Corporation (ABSI) - SC 13G SEC Filings 02/13/2024
Absci Corporation (ABSI) - SC 13G/A SEC Filings 02/09/2024
Absci Corporation (ABSI) - 4 SEC Filings 02/05/2024
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 01/08/2024
Absci Corporation (ABSI) - 4 SEC Filings 01/04/2024
Absci Corporation (ABSI) - 3 SEC Filings 01/04/2024
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 12/20/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 12/07/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 12/04/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 11/14/2023
Absci Corporation (ABSI) - 10-Q - Quarterly Report SEC Filings 11/14/2023
Absci Corporation (ABSI) - 4 SEC Filings 10/16/2023
Absci Corporation (ABSI) - 4 SEC Filings 09/06/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 09/05/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 08/17/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 08/14/2023
Absci Corporation (ABSI) - 10-Q - Quarterly Report SEC Filings 08/14/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 06/16/2023
Absci Corporation (ABSI) - 424B5 SEC Filings 06/16/2023
Absci Corporation (ABSI) - 4 SEC Filings 06/16/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 06/06/2023
Absci Corporation (ABSI) - 4 SEC Filings 06/06/2023
Absci Corporation (ABSI) - 3 SEC Filings 06/06/2023
Absci Corporation (ABSI) - 10-K/A - Current report SEC Filings 05/30/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 05/15/2023
Absci Corporation (ABSI) - 10-Q - Quarterly Report SEC Filings 05/15/2023
Absci Corporation (ABSI) - SC 13D/A SEC Filings 05/08/2023
Absci Corporation (ABSI) - DEFA14A SEC Filings 04/28/2023
Absci Corporation (ABSI) - DEF 14A SEC Filings 04/28/2023
Absci Corporation (ABSI) - PRE 14A SEC Filings 04/12/2023
Absci Corporation (ABSI) - S-8 SEC Filings 03/30/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 03/30/2023
Absci Corporation (ABSI) - 10-K - Current report SEC Filings 03/30/2023
Absci Corporation (ABSI) - SC 13D/A SEC Filings 03/20/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 03/10/2023
Absci Corporation (ABSI) - 4 SEC Filings 03/03/2023
Absci Corporation (ABSI) - SC 13G/A SEC Filings 02/14/2023
Absci Corporation (ABSI) - SC 13G SEC Filings 02/13/2023
Absci Corporation (ABSI) - SC 13D/A SEC Filings 02/13/2023
Absci Corporation (ABSI) - SC 13G/A SEC Filings 02/09/2023
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 12/16/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 11/09/2022
Absci Corporation (ABSI) - 10-Q - Quarterly Report SEC Filings 11/09/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 11/02/2022
Absci Corporation (ABSI) - 4 SEC Filings 11/02/2022
Absci Corporation (ABSI) - 3 SEC Filings 11/02/2022
Absci Corporation (ABSI) - 4 SEC Filings 10/24/2022
Absci Corporation (ABSI) - 4 SEC Filings 10/05/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 10/04/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 09/20/2022
Absci Corporation (ABSI) - EFFECT SEC Filings 09/06/2022
Absci Corporation (ABSI) - EFFECT SEC Filings 09/06/2022
Absci Corporation (ABSI) - CORRESP SEC Filings 08/31/2022
Absci Corporation (ABSI) - UPLOAD SEC Filings 08/26/2022
Absci Corporation (ABSI) - S-3 SEC Filings 08/24/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 08/11/2022
Absci Corporation (ABSI) - 10-Q - Quarterly Report SEC Filings 08/11/2022
Absci Corporation (ABSI) - SC 13D/A SEC Filings 07/21/2022
Absci Corporation (ABSI) - SC 13D/A SEC Filings 07/20/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 07/14/2022
Absci Corporation (ABSI) - 4 SEC Filings 07/01/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 06/10/2022
Absci Corporation (ABSI) - 4 SEC Filings 06/10/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 05/11/2022
Absci Corporation (ABSI) - 10-Q - Quarterly Report SEC Filings 05/11/2022
Absci Corporation (ABSI) - DEFA14A SEC Filings 04/26/2022
Absci Corporation (ABSI) - DEF 14A SEC Filings 04/26/2022
Absci Corporation (ABSI) - 4/A SEC Filings 04/06/2022
Absci Corporation (ABSI) - S-8 SEC Filings 03/22/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 03/22/2022
Absci Corporation (ABSI) - 10-K - Current report SEC Filings 03/22/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 03/21/2022
Absci Corporation (ABSI) - 4 SEC Filings 03/21/2022
Absci Corporation (ABSI) - 3 SEC Filings 03/21/2022
Absci Corporation (ABSI) - 4 SEC Filings 02/23/2022
Absci Corporation (ABSI) - SC 13G SEC Filings 02/14/2022
Absci Corporation (ABSI) - SC 13G SEC Filings 02/11/2022
Absci Corporation (ABSI) - 4 SEC Filings 02/10/2022
Absci Corporation (ABSI) - SC 13G/A SEC Filings 02/09/2022
Absci Corporation (ABSI) - 4 SEC Filings 01/24/2022
Absci Corporation (ABSI) - 4 SEC Filings 01/19/2022
Absci Corporation (ABSI) - 4 SEC Filings 01/11/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 01/10/2022
Absci Corporation (ABSI) - 4 SEC Filings 01/10/2022
Absci Corporation (ABSI) - 3 SEC Filings 01/10/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 01/07/2022
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 11/09/2021
Absci Corporation (ABSI) - 10-Q - Quarterly Report SEC Filings 11/09/2021
Absci Corporation (ABSI) - SC 13G SEC Filings 10/12/2021
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 09/07/2021
Absci Corporation (ABSI) - 10-Q - Quarterly Report SEC Filings 09/07/2021
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 08/24/2021
Absci Corporation (ABSI) - 4 SEC Filings 08/17/2021
Absci Corporation (ABSI) - SC 13D SEC Filings 08/02/2021
Absci Corporation (ABSI) - SC 13D SEC Filings 07/29/2021
Absci Corporation (ABSI) - S-8 SEC Filings 07/28/2021
Absci Corporation (ABSI) - 4 SEC Filings 07/28/2021
Absci Corporation (ABSI) - 8-K - Current report SEC Filings 07/26/2021
Absci Corporation (ABSI) - 424B4 SEC Filings 07/23/2021
Absci Corporation (ABSI) - EFFECT SEC Filings 07/22/2021
Absci Corporation (ABSI) - EFFECT SEC Filings 07/21/2021
Absci Corporation (ABSI) - CERT SEC Filings 07/21/2021
Absci Corporation (ABSI) - 8-A12B SEC Filings 07/21/2021
Absci Corporation (ABSI) - 3 SEC Filings 07/21/2021
Absci Corporation (ABSI) - UPLOAD SEC Filings 07/20/2021
Absci Corporation (ABSI) - SEC STAFF LETTER SEC Filings 07/20/2021
Absci Corporation (ABSI) - S-1/A SEC Filings 07/20/2021
Absci Corporation (ABSI) - CORRESP SEC Filings 07/20/2021
Absci Corporation (ABSI) - S-1/A SEC Filings 07/19/2021
Absci Corporation (ABSI) - CORRESP SEC Filings 07/19/2021
Absci Corporation (ABSI) - S-1/A SEC Filings 07/15/2021
Absci Corporation (ABSI) - CORRESP SEC Filings 07/15/2021
Absci Corporation (ABSI) - UPLOAD SEC Filings 07/14/2021
Absci Corporation (ABSI) - SEC STAFF LETTER SEC Filings 07/08/2021
Absci Corporation (ABSI) - S-1/A SEC Filings 07/08/2021
Absci Corporation (ABSI) - CORRESP SEC Filings 07/08/2021
Absci Corporation (ABSI) - UPLOAD SEC Filings 07/02/2021
Absci Corporation (ABSI) - S-1 SEC Filings 06/30/2021
Absci Corporation (ABSI) - DRS/A SEC Filings 06/16/2021
Absci Corporation (ABSI) - DRSLTR SEC Filings 06/15/2021
Absci Corporation (ABSI) - UPLOAD SEC Filings 06/04/2021
Absci Corporation (ABSI) - DRS SEC Filings 05/06/2021
Absci Corporation (ABSI) - D/A SEC Filings 03/30/2021
Absci Corporation (ABSI) - D SEC Filings 03/30/2021
Absci Corporation (ABSI) - D/A SEC Filings 02/26/2021
Absci Corporation (ABSI) - D SEC Filings 10/30/2020
Absci Corporation (ABSI) - D SEC Filings 12/19/2019
Absci Corporation (ABSI) - D SEC Filings 06/08/2018
Absci Corporation (ABSI) - D SEC Filings 04/21/2016

Press Releases

StockPrice Release
Absci reports business updates and fourth quarter and full year 2023 financial and operating results 03/21/2024
Absci announces closing of public offering of common stock including full exercise of the underwriters' option to purchase additional shares 03/01/2024
Absci announces pricing of public offering of common stock 02/27/2024
Absci announces proposed public offering of common stock 02/27/2024
Absci initiates ind-enabling studies for abs-101, a potential best-in-class anti-tl1a antibody de novo designed and optimized using generative ai 02/21/2024
Absci appoints professor sir mene pangalos to its board of directors 01/10/2024
Absci to participate in the 26th annual needham growth conference 01/03/2024
Absci to participate in the 42nd annual j.p. morgan healthcare conference 12/28/2023
Absci and precisionlife announce strategic r&d partnership to jointly develop ai-enabled drug pipeline 12/20/2023
Absci announces collaboration with astrazeneca to advance ai-driven oncology candidate 12/04/2023
Absci to participate in the piper sandler 35th annual healthcare conference 11/15/2023
Absci reports business updates and third quarter 2023 financial and operating results 11/14/2023
Almirall and absci announce ai drug discovery partnership to rapidly develop novel treatments for dermatological diseases 11/14/2023
Almirall and absci announce ai drug discovery partnership to rapidly develop novel treatments for dermatological diseases 11/14/2023
Absci to participate in upcoming investor conferences 10/26/2023
Absci announces speaker lineup for inaugural r&d day, including renowned global business leader sandi peterson and vp of applied research at nvidia jonathan cohen 09/21/2023
Absci to host r&d day on october 4, 2023 09/06/2023
Absci to participate in upcoming investor conferences 08/28/2023
Absci reports business updates and second quarter 2023 financial and operating results 08/14/2023
Absci appoints zach jonasson, ph.d., as chief financial officer and chief business officer 08/14/2023
Absci and caltech join forces, bolstered by major grant, to accelerate affordable hiv therapeutic vaccine development 08/10/2023
Absci to participate in the ubs medtech, tools and genomics summit 2023 08/01/2023
Absci to participate in the morgan stanley 2nd annual biotechnology ai summit 06/15/2023
Absci evolves its board of directors with healthtech luminary frans van houten, former ceo of philips 06/06/2023
University of oxford's kennedy institute of rheumatology partners with absci to accelerate ai-driven immunotherapies 05/11/2023
Absci to participate in the 22nd annual needham virtual healthcare conference 04/06/2023
Absci reports fourth quarter and full year 2022 financial and operating results 03/30/2023
Absci to participate in the b. riley securities' life sciences tools conference - proteomics setting the blueprint for innovative drug creation 03/23/2023
Absci to participate in the keybanc capital markets life sciences & medtech investor forum 03/07/2023
Absci to participate in the 43rd annual cowen health care conference 02/21/2023
St. john's cancer institute partners with absci to expedite development of cancer therapies 02/09/2023
Absci deepens scientific advisory board to accelerate generative ai drug creation 02/08/2023
Absci to participate in the 41st annual j.p. morgan healthcare conference 01/08/2023
Absci to participate in the 41st annual j.p. morgan healthcare conference 12/28/2022
Absci to participate in the berenberg discover ai seminar 11/23/2022
Absci to participate in the piper sandler healthcare conference 11/17/2022
Absci reports third quarter 2022 financial results 11/09/2022
Absci to participate in the stifel healthcare conference 11/02/2022
Absci appoints veteran pharma executive andreas busch, phd as chief innovation officer 10/04/2022
Absci to participate at the inaugural gilmartin group emerging growth company showcase 08/24/2022
Absci reports second quarter 2022 financial results and business update 08/11/2022
Absci to participate in the ubs genomics 2.0 and medtech innovations summit conference 08/01/2022
Absci to participate in the svb securities cyberx: big data, a.i. & machine learning in healthcare event 07/21/2022
Absci prepares for next stage of growth with executive human resources and marketing hires 07/14/2022
Absci enters multi-program collaboration with emerging biotech partner 07/07/2022
Absci reports first quarter 2022 financial and operating results 05/11/2022
Viva biotech announced 2021 annual results: revenue increased by 201.9% yoy, cro business revenue maintained rapid growth with an increase of 68.7% 03/28/2022
Absci reports full year 2021 financial and operating results 03/22/2022
Absci develops groundbreaking machine learning models for in-silico antibody design, powered by nvidia 03/22/2022
2seventy bio reports fourth quarter and full year 2021 financial results and recent operational progress 03/22/2022
Absci appoints dr. andreas busch to board of directors 03/21/2022
Absci to present at global ai conference nvidia gtc 03/16/2022
Absci to participate in upcoming investor conferences 02/17/2022
2seventy bio announces key management appointments 02/14/2022
Absci to participate in the btig medtech, digital health, life science & diagnostic tools conference 02/11/2022
Absci announces research collaboration with merck 01/07/2022
Absci to participate in the 40th annual j.p. morgan healthcare conference 01/05/2022
Absci to participate in the h.c. wainwright bioconnect virtual conference 12/30/2021
Absci to participate in the 40th annual j.p. morgan healthcare conference 12/29/2021
Ice announces annual reconstitution changes in the ice biotechnology index 12/16/2021
Shareholder alert: pomerantz law firm investigates claims on behalf of investors absci corporation - absi 11/28/2021
Shareholder alert: pomerantz law firm investigates claims on behalf of investors absci corporation - absi 11/25/2021
Shareholder alert: pomerantz law firm investigates claims on behalf of investors absci corporation - absi 11/15/2021
Shareholder alert: pomerantz law firm investigates claims on behalf of investors absci corporation - absi 11/15/2021
Beigene and newbridge pharmaceuticals announce approval in saudi arabia of brukinsa® (zanubrutinib) for the treatment of patients with relapsed or refractory mantle cell lymphoma 11/14/2021
Absci reports third quarter 2021 financial and operating results 11/09/2021
Absci to report third quarter financial results on november 9, 2021 10/14/2021
Eqrx and absci announce partnership to discover and develop next-generation protein-based drugs 10/06/2021
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of absci corporation - absi 09/21/2021
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of absci corporation - absi 09/20/2021
Yamaha rightwaters™, famu-fsu college of engineering partner to bring trash interceptor concepts to life 09/16/2021
Absci to participate in the bofa securities 2021 tech solutions for drug discovery conference 09/13/2021
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of absci corporation - absi 09/09/2021
Absci reports second quarter 2021 financial and operating results 09/07/2021
Absci announces pricing of initial public offering 07/21/2021
Lantheus holdings announces fda clearance for ai-enabled automated bone scan index (absi) in prostate cancer on ge healthcare’s xeleris platform 11/13/2020
Adding multimedia velan capital agrees to support merger of lantheus and progenics 04/14/2020
Lantheus and progenics reschedule their respective special meetings of stockholders for proposed merger 04/02/2020

More Headlines

News
The 3 Most Undervalued Penny Stocks to Buy Now: August 2023 Penny stocks are often defined as stocks trading under $5 per share, those with a very low price per share or market capitalization, and are generally higher-risk. Now, despite many such stocks certainly carrying a relatively high risk profile, this often is somewhat offset by higher potential returns. 08/14/2023
Beyond OpenAI: 7 promising startups that have saved lives, sped up drug development and improved manufacturing OpenAI is stealing the spotlight as the definitive artificial-intelligence startup — for now. Backed by Microsoft Corp. MSFT, the progenitor of ChatGPT-4 has become the focus of the AI wave, but other AI startups are emerging in fields including healthcare, education and manufacturing. 06/01/2023
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates Absci Corporation (ABSI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.33 per share a year ago. 05/15/2023
Absci Takes Its Generative AI Antibody Design Platform To Europe Generative AI technology, like ChatGPT, is disrupting many industries including biopharma. For example, Absci is using AI to design & validate de novo antibodies. 02/28/2023
Publicly traded biotech company Absci lays off employees, citing ‘macro-economic conditions' Vancouver, Wash. 08/10/2022
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings. 08/09/2022
Here's Why Absci Corp Shares Are Falling Absci Corp (NASDAQ: ABSI) shares are trading lower by 9.2% at $6.79 after the company reported fourth-quarter earnings results. Absci reported quarterly losses of 28 cents per share. 03/23/2022
Absci to Present at Global AI Conference NVIDIA GTC VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Absci Lead AI Scientist Joshua Meier will be presenting at NVIDIA GTC . 03/16/2022
Is a Surprise Coming for Absci (ABSI) This Earnings Season? Absci (ABSI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. 03/11/2022
Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the following investor conferences. 02/17/2022
Absci (ABSI) Inks Research Agreement With Merck, Stock Up Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs. 01/10/2022
Absci Corp up 50% after announcing research collaboration with Merck Absci Corporation (NASDAQ: ABSI) went up 50% after it announced that it had executed a research and collaboration agreement with Merck, commonly referred to as MSD outside Canada and the US. The company came to this agreement via its AI-powered Integrated Drug Creation Platform. 01/07/2022
DOGZ Alert: Why Pet Penny Stock Dogness Is Running Higher Today Dogness (DOGZ) stock is on a run Friday as investors react to recent volatility surrounding the shares alongside heavy trading. The post DOGZ Alert: Why Pet Penny Stock Dogness Is Running Higher Today appeared first on InvestorPlace. 01/07/2022
ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today Absci (ABSI) stock is flying higher on Friday after announcing a major research collaboration agreement with Merck (MRK). The post ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today appeared first on InvestorPlace. 01/07/2022
Why Absci Shares Are Soaring Today Absci Corp (NASDAQ: ABSI) is trading higher Friday after the company announced a research collaboration with Merck & Co Inc (NYSE: MRK). The collaboration will utilize Absci's AI-powered Integrated Drug Creation Platform. 01/07/2022
Absci stock rockets after collaboration with Merck could lead to more than $600 million in payments Shares of Absci Corp. ABSI, -12.78% skyrocketed 59.1% on heavy volume in premarket trading Friday, after the biotechnology company said it could be eligible to receive up to $610 million in upfront fees and milestone payments from Merck & Co. Inc. MRK, -0.06% as part of a research collaboration agreement. Trading volume ballooned to 9.7 million shares, compared with the full-day average of about 324,800 shares, to make the stock the biggest gainer and most actively traded ahead of the open. 01/07/2022
Absci Stock (ABSI): Why The Price Surged Today The stock price of Absci Corp (NASDAQ: ABSI) increased by over 30% pre-market today. This is why it happened. 01/07/2022
Absci to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference VANCOUVER, Washington, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference. 12/30/2021
Absci Corporation (ABSI) CEO Sean McClain on Q3 2021 Results - Earnings Call Transcript Absci Corporation (ABSI) CEO Sean McClain on Q3 2021 Results - Earnings Call Transcript 11/14/2021
Biotech company Absci, which recently went public, cuts ribbon on new HQ in Vancouver, Wash. Absci cut the ribbon on its new headquarters in Vancouver, Wash. 11/03/2021
Absci to Report Third Quarter Financial Results on November 9, 2021 VANCOUVER, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced it will report financial results for the third quarter 2021 on Tuesday, November 9, 2021. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. 10/14/2021
FMR LLC's Top 5 Buys in September FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graphite Bio Inc. ( GRPH , Financial) and Absci Corp. ( ABSI , Financial), as well as major position boosts in ZoomInfo Technologies Inc. ( ZI , Financial) and Celldex Therapeutics Inc. ( CLDX , Financial). 10/12/2021
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs CAMBRIDGE, Mass., & VANCOUVER, Wash.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced a discovery collaboration. The partnership will leverage Absci's Drug Creation™ technology for discovery and 10/06/2021
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Absci Corporation - ABSI New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation ("Absci" or the "Company") (NASDAQ: ABSI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Absci and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining... 09/21/2021
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Absci Corporation - ABSI NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation ("Absci" or the "Company") (NASDAQ: ABSI). 09/20/2021
Absci to Participate in the BofA Securities 2021 Tech Solutions for Drug Discovery Conference VANCOUVER, Wash., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BofA Securities 2021 Tech Solutions for Drug Discovery Conference. 09/13/2021
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Absci Corporation - ABSI NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation ("Absci" or the "Company") (NASDAQ: ABSI). 09/09/2021
Absci Reports Second Quarter 2021 Financial and Operating Results VANCOUVER, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30, 2021. 09/07/2021
Shares of protein discovery platform Absci pop in market debut Absci Corp., a Vancouver company behind a multi-faceted drug development platform, went public on Thursday. It's another sign of snowballing interest in new approaches to drug development – a traditionally risky business. 07/22/2021
Couchbase and 5 Other Companies Are Going Public. What You Need to Know. Couchbase, Ryan Specialty Group, and four other companies are scheduled to list their shares Thursday as the surge of IPOs continues. 07/22/2021
IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video) Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public today. 07/22/2021
Absci Announces Pricing of Initial Public Offering VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Absci. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci, are expected to be $200.0 million, excluding any exercise of the underwriters' option to purchase additional shares. Absci's common stock is expected to begin trading on the Nasdaq Global Select Market on July 22, 2021, under the ticker symbol “ABSI.” The offering is expected to close on July 26, 2021, subject to the satisfaction of customary closing conditions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. 07/21/2021
AbSci Proposes Terms For $200 Million IPO AbSci Proposes Terms For $200 Million IPO 07/20/2021

Unlock

ABSI Ratings Summary

ABSI Quant Ranking